(XLV) Health Care Sector Fund - Overview

Exchange: NYSE ARCA • Country: USA • Currency: USD • Type: Etf • ISIN: US81369Y2090

Etf: Pharmaceuticals, Equipment, Providers, Biotechnology, Technology

Total Rating 48
Risk 72
Buy Signal -0.07
Risk 5d forecast
Volatility 13.3%
Relative Tail Risk -0.53%
Reward TTM
Sharpe Ratio 0.38
Alpha 0.84
Character TTM
Beta 0.498
Beta Downside 0.497
Drawdowns 3y
Max DD 17.11%
CAGR/Max DD 0.47

Description: XLV Health Care Sector Fund February 11, 2026

The Health Care Select Sector SPDR® Fund (XLV) seeks to replicate the performance of the Health Care Select Sector Index by investing at least 95 % of its assets in the index’s constituents. The index is comprised of companies across pharmaceuticals, health-care equipment & supplies, health-care providers & services, biotechnology, life-sciences tools & services, and health-care technology, and the ETF is classified as non-diversified under SEC rules.

As of the most recent quarter (Q4 2023), XLV carries an expense ratio of 0.12 % and manages roughly $38 billion in assets. Its top five holdings-UnitedHealth Group (≈9.5 % of assets), Johnson & Johnson (≈8.0 %), Pfizer (≈6.5 %), Merck (≈5.8 %), and Abbott Laboratories (≈5.2 %)-account for about 35 % of the portfolio, reflecting the sector’s concentration in a few large firms. Year-to-date performance is +7.8 %, outpacing the broader S&P 500’s +6.4 % return.

Key drivers of the health-care sector’s outlook include the U.S. population’s aging trajectory (the 65-plus cohort is projected to reach 73 million by 2035, boosting demand for services and pharmaceuticals), sustained federal health-care spending growth averaging 5.5 % annually, and robust biotech R&D financing, which hit a record $43 billion in 2023, fueling pipeline expansion and potential revenue upside for XLV’s biotech constituents.

For a deeper, data-rich analysis of XLV’s valuation dynamics, you might explore the fund on ValueRay.

Altman Z''

Beneish M

DSRI: none (Receivables none/none, Revenue 0.0/0.0)
GMI: 1.00 (fallback, negative margins)
AQI: none (AQ_t none / AQ_t-1 none)
SGI: none (Revenue 0.0 / 0.0)
TATA: none (NI 0.0 - CFO 0.0) / TA none)
Beneish M-Score: cannot calculate (missing components)

What is the price of XLV shares?

As of February 17, 2026, the stock is trading at USD 157.67 with a total of 16,647,400 shares traded.
Over the past week, the price has changed by +0.86%, over one month by +1.24%, over three months by +4.38% and over the past year by +11.02%.

Is XLV a buy, sell or hold?

Health Care Sector Fund has no consensus analysts rating.

What are the forecasts/targets for the XLV price?

Issuer Target Up/Down from current
Wallstreet Target Price - -
Analysts Target Price - -

XLV Fundamental Data Overview February 14, 2026

Revenue TTM = 0.0 USD
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 41.69b USD (41.69b + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 41.69b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 41.69b / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 7.75% (E(41.69b)/V(41.69b) * Re(7.75%) + (debt-free company))
Discount Rate = 7.75% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Fair Price DCF = unknown (Cash Flow 0.0)

Additional Sources for XLV ETF

News: Wall Street Journal | Benzinga | Yahoo Finance
Fund Manager Positions: Dataroma | Stockcircle